Alligator Bioscience AB’s Post

Thanks to Mervyn Turner, previously of Merck, who recently sent me an older 2017 article on the history of Pembro from Forbes written by David Shaywitz, MD, PhD Still a super interesting read in case you’re a historian of biotech! (I’ll make sure all my students read it!!!) I think the lessons learned are still relevant to our industry: * Drug development is never linear! This drug was on the outlicensing list!!! * Commerical didn’t like biomarkers at the time but it saved the lung program. * Be creative in your trial designs to do a full exploration of dose and schedule. * Work closely with the regulatory agencies * If you have a winner, make sure to maximize its potential, especially in the era of IRA.

KACTUS at Festival of Biologics 2024, Booth 517 📍 Mark your calendars! KACTUS is proud to sponsor America's Most Exciting Biologics Event: Festival of Biologics 2024. Join us in sunny San Diego at the San Diego Convention Center from April 15-17. 🔬 Presentation Spotlight: Don't miss out on the insights by Xiaoyuan Ran, our Director of R&D. Catch her talk on "Transforming Tumor Research: Engineering MHCs as Versatile Reagents" on April 15 at 3pm. 📊 Poster Presentations: Explore our innovative research through five engaging posters: #77: Transforming Tumor Research: Engineering MHCs as Versatile Reagents #78: GPCR VLPs & Nanodiscs for Drug Discovery #79: Tailored AAV Solutions: ELISA Kits and Customized Variant Kit Development #80: Enhancing Cell Therapy with GMP-Grade Cas9 Nuclease Exhibiting Superior Quality and Batch Consistency in Gene Editing #81: The Second-Generation High-Fidelity Cytosine Base Editor AccuBaseTM Can Proficiently Modify Multiple Genes Within A Human Primary T cell While Minimizing Off-target Effects For more details and to join us on this biologics voyage, click here: https://bit.ly/4cRcMdZ #KACTUS #festivalofbiologicsUSA #Biotech #Innovation #DrugDiscovery #antibodytherapeutics #antibodydiscovery

Thoughts on this? >> Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #competitivemarketing #pharma

In a recent BioSpace piece, MAIA CEO Vlad Vitoc “lauded successful recent Phase III trial successes as welcome advancements, noting that they will improve care options for patients beyond what is currently available.” Read the full article here: https://bit.ly/4d2yFan #Biotech #Biopharma #NSCLC #OncNews

You want to prepare for deal-making? My colleague Yan Jiang helps you to find your way through the latest pharma deal trends! Sign up for tomorrow and many more expert talks to come. Looking forward to seeing you!

Join us tomorrow at the 2nd Oligonucleotide Manufacturing Symposium, featuring Technical Director Adrian La Porta. The event will take place at the CPI Medicines Manufacturing Innovation Centre in Glasgow, where key stakeholders from the pharmaceutical sector will gather to discuss emerging process technologies in oligonucleotide therapeutics. These innovative DNA or RNA fragments are transforming the treatment of diseases by modulating protein expression through various mechanisms. The symposium will focus on developing and scaling these processes to manufacture therapies effectively. These advances have the potential to address a broad range of diseases, from cancer to Alzheimer’s, paving the way for new treatments for conditions currently deemed untreatable and improving therapies for widespread illnesses like heart disease. Learn more: https://lnkd.in/eWHKy2kC #BrydenWood #OligonucleotideSymposium #PharmaceuticalInnovation #pharma

🎤 Aegle Therapeutics Presenting at Biotech Showcase™!    Shelley A. Hartman, CEO of Aegle Therapeutics, will present on the company’s work in Immunology, Inflammation, and Orphan/Rare Diseases. Founded in 2018 as a private company, Aegle Therapeutics is advancing a clinical trial for recessive dystrophic Epidermolysis Bullosa (#RDEB), a rare and challenging condition. Early clinical data with their lead candidate, AGLE-102, shows promising potential for regenerative healing, including dermal remodeling of chronic RDEB wounds with significant scarring. AGLE-102 utilizes extracellular vesicles derived from MSCs to drive impactful healing in patients. 🗓️ Register to attend and learn more: https://lnkd.in/evchNnAj  Biotech Showcase, alongside Seed Showcase and TechBio Showcase, provides private and micro- to mid-cap biotechnology companies with a premier platform to present their innovations directly to investors and biopharmaceutical executives. Join us in San Francisco, January 13–15, 2025, with virtual sessions on January 16–17 on the partneringONE platform, to showcase your organization and connect with strategic partners. 📝 Apply to present your innovations: https://lnkd.in/e449f9Zg 🌁 What to Expect at Biotech Showcase: https://lnkd.in/eudKKs_2  #BiotechShowcase #DemyColton #EBDGroup #Biotech #Immunology #Inflammation #RareDisease #Innovation #Investors #Partnering #AegleTherapeutics Demy-Colton EBD Group

Join the Webinar! Unlock the potential of Quanterix's Accelerator Laboratory in an upcoming webinar! Gain insights from Dr. Havrda, whose work has led to the development of highly sensitive assays for inflammasome-related proteins. Register today!  #Pharma #Immunoassays

The Life Sciences industry continues to advance with groundbreaking progress and key achievements this week. Here are some of the most remarkable updates: Akero Therapeutics has dosed its first patient in the Phase 3 SYNCHRONY Outcomes Study of Efruxifermin for patients with compensated cirrhosis due to MASH. CytomX Therapeutics initiated dosing of its first patient with CX-801, a dually-masked interferon-alpha 2b PROBODY, in a Phase 1 study targeting patients with solid tumors. Rezolute, Inc. received FDA clearance to lift partial clinical holds on RZ358 for the treatment of congenital hyperinsulinism, allowing U.S. inclusion in its ongoing Phase 3 study. Terns Pharmaceuticals reported positive Phase 1 clinical trial results for TERN-601, a once-daily oral GLP-1R agonist aimed at treating obesity. Culture Biosciences announced a collaboration with Google Cloud to revolutionize bioprocess development. Innovent Biologics delivered an oral presentation on Phase 1 clinical data of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in advanced non-small cell lung cancer at the 2024 WCLC. Inflammatix, Inc. secured $57 million to advance its novel diagnostic for patients with suspected infections or sepsis. These developments reflect the relentless drive for innovation within the life sciences sector. Stay connected as we continue to monitor the latest advancements and breakthroughs in this dynamic industry! #LifeScience #Biotech #HealthTech #Innovation #AI #Healthcare #ClinicalTrials #FDAApproval #Pharma #HealthcareInnovation #MedTech #Biopharma #DrugDevelopment #ResearchAndDevelopment #BiotechNews #Pharmaceuticals #SFBay #DrugDiscovery #Genomics